Crossmark

Targeted antitumor prodrug therapy using CNGRC-yCD fusion protein in combination with 5-fluorocytosine

Crossref DOI link: https://doi.org/10.1186/s12929-016-0227-6

Published Online: 2016-01-22

Published Print: 2016-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Li, Jia-Je

Chang, Shun-Fu

Liau, I-Iu

Chan, Pei-Chia

Liu, Ren-Shyan

Yen, Sang-Hue

Wang, Hsin-Ell

Chang, Cheng Allen https://orcid.org/0000-0002-9753-5057
Funding

Funding for this research was provided by:

National Science Council of Taiwan (NSC 101-2627-M-010-001)

National Science Council of Taiwan (NSC 101-2627-M-010-004)

National Science Council of Taiwan (NSC 102-2627-M-010-002)

National Science Council of Taiwan (NSC 102-2627-M-010-001)

Ministry of Science and Technology, Taiwan (MOST 103-2627-M-010-002)

Ministry of Science and Technology, Taiwan (MOST 103-2627-M-010-001)

Veterans General Hospitals University System of Taiwan Joint Research Program (VGHUST104-G7-4-1)

Veterans General Hospitals University System of Taiwan Joint Research Program (VGHUST104-G7-4-2)

Veterans General Hospitals University System of Taiwan Joint Research Program (VGHUST104-G7-4-3)
License Information

Text and Data Mining valid from 2016-01-22
More Information

Article History

Received: 13 June 2015

Accepted: 12 January 2016

First Online: 22 January 2016